Mostrar el registro sencillo del ítem

dc.contributor.authorGarcía-Torres, Francisco
dc.contributor.authorTejero‑Perea, Adrián
dc.contributor.authorGómez Solís, Ángel
dc.contributor.authorCastillo-Mayén, Rosario
dc.contributor.authorJaén Moreno, María José
dc.contributor.authorLuque, Bárbara
dc.contributor.authorGálvez Lara, Mario
dc.contributor.authorSánchez Raya, Araceli
dc.contributor.authorJabłoński, Marcin J.
dc.contributor.authorRodríguez-Alonso, Beatriz
dc.contributor.authorAranda Aguilar, Enrique
dc.date.accessioned2024-06-25T09:24:43Z
dc.date.available2024-06-25T09:24:43Z
dc.date.issued2022
dc.identifier.urihttp://hdl.handle.net/10396/28555
dc.description.abstractBackground: Cancer survivors frequently develop cognitive impairment, which negatively affects their quality of life and emotional well-being. This study compares the effectiveness of a well-established treatment (neuropsychological treatment) with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) to reduce these cognitive deficits and evaluate the effect of both treatments on anxiety-depressive symptoms and the quality of life of cancer survivors. Methods: A three-arm, randomized superiority clinical trial with a pre-post and repeated follow-up measures intergroup design using a 1:1:1 allocation ratio will be performed. One hundred and twenty-three cancer survivors with mild to moderate cognitive impairment will be randomly assigned to one of the study interventions: a cognitive rehabilitation intervention group, an intervention group with UP intervention, or a control group on the waiting list. The primary outcome is to observe a significant improvement in cognitive function in both intervention groups and a significant decrease in emotional impairments in comparison with the waitlist group. Improvements in anxiety, depression, and quality of life are also expected as secondary outcomes. These results will be maintained at 6 months of follow-up. Discussion: The aim of this trial is to test the efficacy of the UP intervention in reducing cognitive deficits in breast cancer survivors. The results of this trial may be useful in reducing the presence of cognitive problems in cancer survivors and improving their emotional state and quality of life.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.rightshttps://creativecommons.org/licenses/by/4.0/es_ES
dc.sourceGarcía-Torres, F., Tejero-Perea, A., Gómez-Solís, Á. et al. Effectiveness of the Unified Barlow Protocol (UP) and neuropsychological treatment in cancer survivors for cognitive impairments: study protocol for a randomized controlled trial. Trials 23, 819 (2022).es_ES
dc.subjectOncologyes_ES
dc.subjectCanceres_ES
dc.subjectUnified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)es_ES
dc.subjectCognitive impairmentes_ES
dc.subjectQuality of lifees_ES
dc.subjectAnxietyes_ES
dc.subjectDepressiones_ES
dc.titleEffectiveness of the Unified Barlow Protocol (UP) and neuropsychological treatment in cancer survivors for cognitive impairments: study protocol for a randomized controlled triales_ES
dc.typeinfo:eu-repo/semantics/annotationes_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s13063-022-06731-wes_ES
dc.relation.projectIDJunta de Andalucía.1380800-R.es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem